|

Methylprednisolone Clinical Trials

18 actively recruiting trials across 11 locations

No change since May 2026

Also known as: Adlone, Caberdelta M, DepMedalone, Depo Moderin, Depo-Medrol, Solu-Medrol, Methyl Prednisolonate +27 more

Pipeline

Early 1: 1Phase 1: 2Phase 2: 6Phase 3: 4Phase 4: 2Phase 1/2: 1

Top Sponsors

  • Oncotherapeutics3
  • M.D. Anderson Cancer Center2
  • Sun Yat-sen University1
  • Niguarda Hospital1
  • National Institute of Neurological Disorders and Stroke (NINDS)1

Indications

Other5 trials

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
Phase 3
Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)
Phase 1/2
Effect of Methylprednisolone on Systemic Inflammatory Response During Pediatric Congenital Open-Heart Surgery
Phase 4
Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma
Phase 2
Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia
N/A

West Hollywood, California2 trials

A Trial of Selinexor, Ruxolitinib and Methylprednisolone

Berenson Cancer Center

Phase 1
Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma

Berenson Cancer Center

Early 1

Houston, Texas2 trials

Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure

M D Anderson Cancer Center

N/A
Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

M D Anderson Cancer Center

Phase 2

Birmingham, Alabama1 trial

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Children's Hospital of Alabama

Phase 2

Gilbert, Arizona1 trial

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Banner MD Anderson Cancer Center ( Site 0165)

Phase 3

Alhambra, California1 trial

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Global Oncology, Inc.

Phase 1

Loma Linda, California1 trial

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

Loma Linda University health

Phase 2

Los Angeles, California1 trial

TReatment for ImmUne Mediated PathopHysiology

Children's Hospital Los Angeles

Phase 2

San Diego, California1 trial

MYTHS - MYocarditis THerapy With Steroids

University of California San Diego

Phase 3

Atlanta, Georgia1 trial

Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial

Emory University Hospital/Winship Cancer Institute

Phase 4

Chicago, Illinois1 trial

A Study of Methylprednisolone in People Having Liver Surgery

Rush University Medical Center (Data collection only)

Phase 3

Bethesda, Maryland1 trial

Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques

National Institutes of Health Clinical Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.